Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Teva Pharmaceutical Industries Ltd (TEVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 33,162,240
  • Shares Outstanding, K 1,016,000
  • Annual Sales, $ 21,903 M
  • Annual Income, $ 329,000 K
  • 36-Month Beta 0.47
  • Price/Sales 1.50
  • Price/Cash Flow 4.92
  • Price/Book 1.03

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.80 +6.61%
on 07/11/17
33.82 -2.91%
on 07/13/17
+0.22 (+0.69%)
since 06/23/17
3-Month
27.59 +19.01%
on 05/31/17
33.82 -2.91%
on 07/13/17
+2.07 (+6.75%)
since 04/25/17
52-Week
27.59 +19.01%
on 05/31/17
55.79 -41.15%
on 08/04/16
-21.50 (-39.56%)
since 07/25/16

Most Recent Stories

More News
NICE Recommends CINQAERO(R) (reslizumab) for the Treatment of Severe Eosinophilic Asthma

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the National Institute for Health and Care Excellence (NICE) in England has recommended CINQAERO(R) (reslizumab)...

TEVA : 32.80 (+1.02%)
Nektar's NKTR-181 Positive in Human Abuse Potential Study

Positive top line results from an oral human abuse potential (HAP) study, evaluating the opioid analgesic candidate -- NKTR-181 -- to assess abuse potential compared with oxycodone, nudged up Nektar's...

COLL : 13.15 (-0.38%)
ENDP : 11.57 (-0.86%)
TEVA : 32.80 (+1.02%)
NKTR : 23.17 (+0.96%)
AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise

AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).

AZN : 33.80 (-0.15%)
TEVA : 32.80 (+1.02%)
RHHBY : 31.8300 (-1.00%)
SNY : 48.10 (+0.82%)
Target and Yandex climb while Delta slides

NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday:

TIF : 95.29 (+1.98%)
TGT : 55.20 (+2.13%)
YNDX : 31.75 (-0.28%)
NRG : 25.06 (-0.87%)
TEVA : 32.80 (+1.02%)
CBSH : 58.89 (+1.20%)
DAL : 51.27 (-0.50%)
Lilly Gets Favorable Ruling in Alimta Patent Lawsuit in UK

Eli Lilly and Company (LLY) announced that it has received favorable ruling from the UK Supreme Court in a patent lawsuit against generic drugmaker, Actavis related to its key cancer drug, Alimta (pemetrexed...

LLY : 81.69 (-3.60%)
AGN : 254.83 (+0.52%)
NVS : 84.26 (-0.04%)
TEVA : 32.80 (+1.02%)
VIVUS Settles with Teva on Weight Management Drug Generic

VIVUS, Inc. (VVUS) announced that it has entered into a settlement agreement with Teva Pharmaceutical Industries Limited (TEVA), thereby resolving a three-year old patent litigation related to its weight...

AGEN : 5.09 (-5.21%)
VVUS : 1.20 (-0.83%)
RDY : 41.77 (+0.60%)
TEVA : 32.80 (+1.02%)
The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva

The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva

ESPR : 48.75 (-0.10%)
MRK : 62.31 (-0.42%)
TEVA : 32.80 (+1.02%)
RHHBY : 31.8300 (-1.00%)
SNY : 48.10 (+0.82%)
Teva's (TEVA) Filing for Biosimilar Rituxan Accepted by FDA

Teva Pharmaceutical Industries Ltd. (TEVA) and Korean partner Celltrion, Inc., announced that the FDA has accepted for review their Biologics License Application (BLA) for CT-P10, a proposed biosimilar...

NVS : 84.26 (-0.04%)
TEVA : 32.80 (+1.02%)
RHHBY : 31.8300 (-1.00%)
AMGN : 180.92 (-0.08%)
Pharma Stock Roundup: Sanofi RA Drug Gets EU Nod, Merck CETP Inhibitor Surprises

Merck's (MRK) results on its CETP inhibitor took the investment community by surprise while Sanofi gained EU approval for its rheumatoid arthritis (RA) drug.

ESPR : 48.75 (-0.10%)
AZN : 33.80 (-0.15%)
MRK : 62.31 (-0.42%)
TEVA : 32.80 (+1.02%)
RHHBY : 31.8300 (-1.00%)
SNY : 48.10 (+0.82%)
BMY : 56.00 (+0.72%)
Corporate News Blog - Aralez Announced District Court Decision to Uphold VIMOVO Patents

LONDON, UK / ACCESSWIRE / June 29, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), following which we have...

ARLZ : 1.40 (+1.45%)
HZNP : 13.48 (+2.43%)
TEVA : 32.80 (+1.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More

Business Summary

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended...

See More

Support & Resistance

2nd Resistance Point 32.99
1st Resistance Point 32.73
Last Price 32.80
1st Support Level 32.26
2nd Support Level 32.05

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.